|
|
|
MedChemExpress (MCE) 提供多元的高品質研究化學品和生物化學品，包括用於實驗室和科學用途的新型生物活性化合物、染劑、胜肽和天然化合物。
|
|
• 超過 50,000種生物活性分子化合物的庫存
|
|
|
• 超過針對20多種訊號路徑中的1000多種關鍵目標蛋白的化合物
|
|
• 產品均附上品質報告書（LC/MS、NMR 和 HPLC）
|
|
• 每月發佈超過1000種最新的產品
|
|
• 提供詳細Datasheet的資訊
|
|
|
• 高純度和有競爭力的價格
|
|
|
• 快速到貨
|
|
|
|
|
|
|
Research Area: Apoptosis/Autophagy/ROS
|
|
|
|
•
|
An initiator of blue-light-induced apoptosis.
|
|
•
|
Mediates autophagy and the production of reactive oxygen species.
|
|
•
|
The first fluorophore isolated from RPE lipofuscin, damages RPE cells and used in the study for retinal degenerative diseases.
|
|
|
|
Solubility: DMSO : 100 mg/mL (141.66 mM; Need ultrasonic)
|
|
|
|
CAS No.: 2102347-47-5
|
|
|
|
|
Research Area: Phospholipase/Cardiovascular Disease
|
|
|
|
•
|
An PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke.
|
|
•
|
Protects blood-brain barrier integrity from ischemia-induced injury.
|
|
|
|
Solubility: DMSO : 100 mg/mL (114.53 mM; Need ultrasonic)
|
|
|
|
CAS No.: 2259884-03-0
|
|
|
|
|
Research Area: GLP Receptor/Diabetes
|
|
|
|
•
|
A long-acting synthetic oxyntomodulin analog.
|
|
•
|
A glucagon-like peptide-1 (GLP-1R)/glucagon receptor GCGR co-agonist.
|
|
•
|
Used for the research in obesity and type 2 diabetes (T2D).
|
|
|
|
Solubility: H2O : 22.22 mg/mL (ultrasonic and adjust pH to 2 with HCl)
|
|
|
|
CAS No.: 875258-85-8
|
|
|
|
|
Research Area: GHSR/Metabolic Disease
|
|
|
|
•
|
A potent and orally active ghrelin receptor (GHSR) antagonist.
|
|
•
|
Produces a greater improvement in glucose homeostasis in rats.
|
|
•
|
Inhibits the calcium response induced by ghrelin.
|
|
|
|
Solubility: DMSO : 100 mg/mL (244.20 mM; Need ultrasonic)
|
|
|
|
CAS No.: 16705-03-6
|
|
|
|
|
|
Research Area: NF-κB/AMPK/Metabolic Disease/Inflammation/Immunology
|
|
|
|
•
|
A natural mitochondria-targeted antioxidant.
|
|
•
|
Alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway.
|
|
•
|
An AMPK activator for non-alcoholic fatty liver disease (NAFLD) study.
|
|
|
|
Solubility: DMSO : 2 mg/mL (5.56 mM; Need ultrasonic)
|
|
|
|
MCE 最新化合物庫
|
|
|
|
膜蛋白是附著在細胞、胞器膜上等相關的蛋白質分子。 依據蛋白質與膜的結合方式，膜蛋白可分為兩類：整合膜蛋白和外在膜蛋白。 在人類大約有 30% 的基因編碼膜蛋白。 膜蛋白具有多種對於生存重要的功能，例如訊號傳遞、分子或離子運輸、酶催化和細胞間聯繫。 膜蛋白對於藥物開發也非常重要。 依據文獻指出，目前超過60%的藥物靶點都是膜蛋白。
MCE 提供 6,000 多種針對各種膜蛋白的化合物和 4,000 多種針對各種膜受體的化合物的，可用於膜蛋白或以膜受體為重點的篩選和藥物開發。
|
|
Compound Library
|
Compound Number
|
Description
|
|
Membrane Protein-targeted Compound Library
|
6,000+
|
Targets such as GLUT, GABA Receptor, VEGFR, GPR88, Adrenergic Receptor, 5-HT Receptor, ion channel, etc.
|
|
Membrane Receptor-targeted Compound Library
|
4,000+
|
Targets such as FGFR, TRP Channel, VEGFR, TNF Receptor, Opioid Receptor, 5-HT Receptor, ion channel, etc.
|
|
|
|
|
|
|
MCE基底膜基質
|
|
|
|
|
基底膜是體內細胞下方的細胞外基質，是從富含細胞外基質蛋白的小鼠腫瘤中所致生產而成的。 其主要成分包括laminin, type IV collagen, heparin acetyl sulfate proteoglycan (HSPG), 和nestin，以及多種生長因子如TGF-β、EGF、IGF、FGF等。
MCE基底膜基質保證不含LDEV，功能驗證數據完整，批次間一致性高，適用於體外3D細胞培養、類器官建立、腫瘤細胞侵襲實驗。
|
|
Product Name
|
Application
|
|
Basement Membrane Matrix (Phenol Red)
|
Cell culture, e.g., epithelial cells; promotes differentiation of multiple cell types, e.g., neurons, hepatocytes.
|
|
Basement Membrane Matrix
|
Cell culture, e.g., epithelial cells; promotes differentiation of multiple cell types, e.g., neurons, hepatocytes. No effect on subsequent color identification experiments.
|
|
Basement Membrane Matrix GFR (Phenol Red)
|
Need to reduce growth factor-induced cell culture, such as osteoblast signaling optimization.
|
|
Basement Membrane Matrix GFR
|
Need to reduce growth factor-induced cell culture, such as osteoblast signaling optimization. No effect on subsequent color identification experiments.
|
|
Basement Membrane Matrix HC (Phenol Red)
|
Angiogenesis experiments, animal models and 3D tumor model construction.
|
|
Basement Membrane Matrix IPSC-qualified
|
Stem cell culture.
|
|
Basement Membrane Matrix for Organoid Culture
|
Organoid construction.
|
|
|
|
|
最新MCE產品引用文獻
|
|
|
Nature.
2023 Jun;618(7966):799-807.
|
|
|
|
Nature.
2023 Jun;618(7966):862-870.
|
|
|
|
Cell.
2023 Jun 22;186(13):2929-2949.e20.
|
|
|
|
Cell.
2023 Jun 8;186(12):2628-2643.e21.
|
|
|
|
|
|
|
|
|
|
|
|
